New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For PFE;ENDP From The Last 14 Days
Check below for free stories on PFE;ENDP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | all recent news | >>
May 22, 2013
08:59 EDTPFEOn The Fly: Pre-market Movers
Subscribe for More Information
08:06 EDTPFEZoetis comments on Pfizer’s split-off plans for remaining interest
Subscribe for More Information
08:04 EDTPFEPfizer announces plan to split-off remainder of Zoetis
Subscribe for More Information
08:02 EDTPFEPfizer announces plan to split-off remainder of Zoetis
Subscribe for More Information
May 21, 2013
07:16 EDTPFEPfizer management to meet with Leerink
Subscribe for More Information
May 20, 2013
17:04 EDTPFEPfizer discontinues phase 3 study of inotuzumab ozogamicin
Subscribe for More Information
May 17, 2013
11:53 EDTENDPOptions with decreasing implied volatility: SGMO ARNA CSC ENDP
Subscribe for More Information
May 16, 2013
10:03 EDTENDPOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:55 EDTPFEBofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call
Subscribe for More Information
08:27 EDTENDPEndo Health upgraded to Buy from Neutral at Buckingham
Buckingham upgraded Endo Health based on attractive risk/reward and expectations for a more detailed strategy from the new CEO, maybe by Q2 results. Price target remains $41.
May 13, 2013
09:27 EDTENDPEndo Health downgraded to Market Perform from Outperform at William Blair
09:25 EDTENDPOn The Fly: Pre-market Movers
Subscribe for More Information
09:04 EDTENDPEndo Health falls 4.8%
Endo Health is down 4.8%, or $1.67, to $33.30
08:13 EDTENDPEndo Health price target lowered to $31 from $35 at Susquehanna
Subscribe for More Information
07:49 EDTENDPFDA decision on Opana a modest positive for Impax, says Leerink
Leerink views the FDA's denial of Endo's (ENDP) Citizen Petition as a modest positive for Impax (IPXL), which it notes is the sole holder of 180 day exclusivity on generic Opana. However, Leerink says upside for Impax will be limited as Actavis (ACT), Sandoz, and Teva (TEVA) have settlements to enter the market starting in June 2013 when Impax's 180-day generic exclusivity expires.
07:45 EDTENDPEndo Health price target lowered to $36 from $42 at Stifel
Subscribe for More Information
07:32 EDTENDPEndo Health downgraded to Sell from Neutral at Lazard Capital
Subscribe for More Information
07:20 EDTENDPEndo Health price target lowered to $37 from $47 at Jefferies
Jefferies lowered its price target for Endo Health after the FDA ruled that crushable Opana generics can come to market. The firm keeps a Buy rating on the stock, saying the company's spending flexibility is underappreciated.
06:48 EDTENDPEndo Health downgraded to Fair Value from Buy at CRT Capital
Subscribe for More Information
May 10, 2013
16:59 EDTENDPEndo Health says FDA denial could cut FY13 adjusted EPS by 55c
Subscribe for More Information
16:29 EDTPFEOn The Fly: Closing Wrap
Subscribe for More Information
15:45 EDTENDPEndo Health trading halted, pending news
15:44 EDTENDPEndo Health denied petition to block Opana ER generics
Subscribe for More Information
12:31 EDTPFEOn The Fly: Midday Wrap
Subscribe for More Information
11:48 EDTPFEDrugmakers to face pressure on U.S. prices, Reuters says
Subscribe for More Information
09:21 EDTPFEOn The Fly: Pre-market Movers
Subscribe for More Information
08:08 EDTPFEPain Therapeutics discloses Pfizer reassessing continued Remoxy partnership
Pain Therapeutics (PTIE) disclosed a letter its CEO was sent from partner Pfizer (PFE) in which the drug maker said it is reassessing its endorsement of the Remoxy program "given the years of delay, additional cost incurred to bring the program to this point and development work left in the program." Pfizer said it will be reaching out to Pain Therapeutics "shortly" to have a confidential discussion about the terms of the companies' contractual agreement over the pain drug. Pfizer that it appears there is a regulatory pathway forward for Remoxy, but that the company does not expect to respond to submit a Complete Response letter for Remoxy to the FDA before mid-2015. Pfizer added in its letter to Pain Therapeutics "no final decision has been made at this time" on how it will proceed with the Remoxy development program. Shares of Pain Therapeutics fell 47% to $2.81 in pre-market trading following the disclosure of the correspondence.
07:46 EDTPFEDURECT says additional clinical studies needed for Remoxy
DURECT (DRRX) announced that Pfizer (PFE) has provided an update on Remoxy in a regulatory filing. Pfizer's disclosure included: "We have been working to address the issues raised in the letter, which primarily relate to manufacturing. We met with the FDA in March 2013 to discuss our plan to address the June 2011 "complete response" letter. We received written guidance from the FDA in May regarding required next steps, including additional clinical studies, to address the letter. Based on this guidance, we are considering our options with respect to Remoxy. If we elect to continue development of Remoxy, we would not expect to submit a response to the 'complete response' letter before mid-2015." DURECT said it understands from Pfizer that additional clinical studies are necessary and include, in part, a pivotal bioequivalence study with the modified formulation to bridge to the clinical data conducted with the original formulation, as well as an abuse potential study with the modified Remoxy formulation. Remoxy is based on DURECT's ORADUR technology. Shares of Pfizer's Remoxy partner Pain Therapeutics (PTIE) are down 56% in pre-market trading, while shares of DURECT are down 13%, or 20c, to $1.39.
May 9, 2013
16:52 EDTENDPBDSI's Phase 3 trials for BEMA Buprenorphine to finish late 2013 or early 2014
Subscribe for More Information
16:44 EDTENDPBlue Ridge Capital reports 5.98% passive stake in Endo Health
Subscribe for More Information
10:17 EDTPFEShire trades higher in London amid takeover chatter, Guardian says
Subscribe for More Information
<< 1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.